 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 December 1996 | Volume 125 Issue 11 | Pages 865-872
Objective: To increase lean body mass and improve health status in patients with wasting associated with the acquired immunodeficiency syndrome (AIDS) by treatment with recombinant human growth hormone (rhGH), recombinant human insulin-like growth factor 1 (rhIGF-1), or both.
Design: Randomized, double-blind, placebo-controlled clinical trial.
Setting: University of New Mexico Clinical Research Center and University of Texas Southwestern Medical Center.
Patients: 60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention. Patients were divided into four groups of 15 patients each.
Intervention: Group 1 received 1.4 mg of rhGH once daily plus placebo twice daily; group 2 received 5 mg of rhIGF-1 twice daily plus placebo once daily; group 3 received 5 mg of rhIGF-1 twice daily plus 1.4 mg of rhGH once daily; and group 4 received placebo three times daily.
Measurements: Body weight, body composition, muscle strength, protein catabolism, quality of life, and immune status were assessed at baseline, and changes in these variables were measured at 6 and 12 weeks.
Results: At 6 weeks, lean body mass had increased and total fat mass had decreased in the groups receiving rhGH, rhIGF-1, or both. Group 3 had the greatest changes in lean body mass (mean ± SE, 3.2 ± 0.59 kg; P < 0.001); only in this group were changes in body mass maintained at 12 weeks. Only patients in group 1 had improvement in muscular strength of the knees and upper body (P = 0.04) and quality of life (P = 0.01). Immunologic function did not improve in any group.
Conclusions: Growth factor therapy had significantly increased lean body mass and decreased fat mass by 6 weeks, but these improvements persisted for 12 weeks only in group 3. Growth factor therapy at the dosages used in this study is not recommended because the magnitude of weight gain was modest and improvements in quality-of-life measures varied.
Deceased.
ARTICLE
Recombinant Human Growth Hormone, Insulin-like Growth Factor 1, and Combination Therapy in AIDS-Associated Wasting
A Randomized, Double-Blind, Placebo-Controlled Trial
Related articles in Annals:
This article has been cited by other articles:
 |
|
 |
|
  T. T. Perls, N. R. Reisman, and S. J. Olshansky Provision or Distribution of Growth Hormone for "Antiaging": Clinical and Legal Issues JAMA, October 26, 2005; 294(16): 2086 - 2090. [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Storer, L. J. Woodhouse, F. Sattler, A. B. Singh, E. T. Schroeder, K. Beck, M. Padero, P. Mac, K. E. Yarasheski, P. Geurts, et al. A Randomized, Placebo-Controlled Trial of Nandrolone Decanoate in Human Immunodeficiency Virus-Infected Men with Mild to Moderate Weight Loss with Recombinant Human Growth Hormone as Active Reference Treatment J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4474 - 4482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Meyerhardt, J. A. Sloan, D. J. Sargent, R. M. Goldberg, M. Pollak, R. F. Morton, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, and C. S. Fuchs Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1402 - 1410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cuerda, A. Zugasti, I. Breton, M. Camblor, P. Miralles, and P. Garcia Treatment With Nandrolone Decanoate and Megestrol Acetate in HIV-Infected Men Nutr Clin Pract, February 1, 2005; 20(1): 93 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A Wainberg, B. G. Brenner, E. Daar, J. M. Gertner, C. Olivier, and S. Kenley Lack of Effect of Recombinant Human Growth Hormone on the In Vitro Activities of Antiretroviral Drugs against Human Immunodeficiency Virus Type 1 Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2337 - 2340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dolan, S. Wilkie, N. Aliabadi, M. P. Sullivan, N. Basgoz, B. Davis, and S. Grinspoon Effects of Testosterone Administration in Human Immunodeficiency Virus-Infected Women With Low Weight: A Randomized Placebo-Controlled Study Arch Intern Med, April 26, 2004; 164(8): 897 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. ROELFSEMA and R. G. CLARK The Growth Hormone and Insulin-Like Growth Factor Axis: Its Manipulation for the Benefit of Growth Disorders in Renal Failure J. Am. Soc. Nephrol., June 1, 2001; 12(6): 1297 - 1306. [Abstract] [Full Text]
|
|
|
|
|
|
Measures of Submaximal Aerobic Performance Evaluate and Predict Functional Response to Growth Hormone (GH) Treatment in GH-Deficient Adults J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4570 - 4577. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. R. Cox, N. E. Morrison, J. L. Sartin, F. C. Buonomo, B. Steele, and H. J. Baker Alterations in the Growth Hormone/Insulin-Like Growth Factor I Pathways in Feline GM1 Gangliosidosis Endocrinology, December 1, 1999; 140(12): 5698 - 5704. [Abstract] [Full Text]
|
|
|
|
|
|
L. E. Levitt Katz, R. J. Ferry Jr., C. A. Stanley, P. F. Collett-Solberg, L. Baker, and P. Cohen Suppression of Insulin Oversecretion by Subcutaneous Recombinant Human Insulin-Like Growth Factor I in Children with Congenital Hyperinsulinism Due to Defective {beta}-Cell Sulfonylurea Receptor J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3117 - 3124. [Abstract] [Full Text]
|
|
|
|
 |
|
 S.-S. Yeh and M. W Schuster Geriatric cachexia: the role of cytokines Am. J. Clinical Nutrition, August 1, 1999; 70(2): 183 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Corcoran and S. Grinspoon Treatments for Wasting in Patients with the Acquired Immunodeficiency Syndrome N. Engl. J. Med., June 3, 1999; 340(22): 1740 - 1750. [Full Text] [PDF]
|
|
|
|
 |
|
 Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease . A Statement of the American Thoracic Society and European Respiratory Society Am. J. Respir. Crit. Care Med., April 1, 1999; 159(4): S2 - 40. [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Bistrian Dietary Treatment in Secondary Wasting and Cachexia J. Nutr., January 1, 1999; 129(1): 290S - 290S. [Full Text] [PDF]
|
|
|
|
|
|
K. Mulligan, V. W. Tai, and M. Schambelan Effects of Chronic Growth Hormone Treatment on Energy Intake and Resting Energy Metabolism in Patients with Human Immunodeficiency Virus-Associated Wasting--A Clinical Research Center Study J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1542 - 1547. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. E. Mulroney, K. J. McDonnell, C. B. Pert, M. R. Ruff, Z. Resch, W. K. Samson, and M. D. Lumpkin HIV gp120 inhibits the somatotropic axis: A possible GH-releasing hormone receptor mechanism for the pathogenesis of AIDS wasting PNAS, February 17, 1998; 95(4): 1927 - 1932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Lamberts, A. W. van den Beld, and A. van der Lely The Endocrinology of Aging Science, October 17, 1997; 278(5337): 419 - 424. [Abstract] [Full Text]
|
|
|
|
|
|
R. Marcus M.D. and G. M. Reaven M.D. Growth Hormone--Ready for Prime Time? J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 725 - 726. [Full Text] [PDF]
|
|
|
|
 |
|
 Growth Hormone and Wasting AIDS Clinical Care, January 1, 1997; 1997(101): 2 - 2. [Full Text]
|
|
|
|
 |
|
 MIXED NEWS ON GROWTH HORMONE Journal Watch (General), December 13, 1996; 1996(1213): 1 - 1. [Full Text]
|
|
Article
